The Management of Iron Chelation Therapy: Preliminary Data from a National Registry of Thalassaemic Patients
Open Access
- 5 June 2011
- journal article
- research article
- Published by Hindawi Limited in Anemia
- Vol. 2011, 1-7
Abstract
Thalassaemia and other haemoglobinopathies constitute an important health problem in Mediterranean countries, placing a tremendous emotional, psychological, and economic burden on their National Health systems. The development of new chelators in the most recent years had a major impact on the treatment of thalassaemia and on the quality of life of thalassaemic patients. A new initiative was promoted by the Italian Ministry of Health, establishing a Registry for thalassaemic patients to serve as a tool for the development of cost-effective diagnostic and therapeutic approaches and for the definition of guidelines supporting the most appropriate management of the iron-chelating therapy and a correct use of the available iron-chelating agents. This study represents the analysis of the preliminary data collected for the evaluation of current status of the iron chelation practice in the Italian thalassaemic population and describes how therapeutic interventions can widely differ in the different patients' age groups.Keywords
This publication has 17 references indexed in Scilit:
- Iron Overload in Sickle Cell DiseaseAdvances in Hematology, 2010
- Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiproneHaematologica, 2009
- Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disordersHaematologica, 2008
- Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood, 2006
- Factors associated with the attitudes and expectations of patients suffering from β‐thalassaemia: a cross‐sectional studyScandinavian Journal of Caring Sciences, 2004
- Pharmacotherapy of iron overload in thalassaemic patientsExpert Opinion on Pharmacotherapy, 2003
- Chelation therapy in β-thalassemia: An optimistic updateSeminars in Hematology, 2001
- Survival and Disease Complications in Thalassemia MajorAnnals of the New York Academy of Sciences, 1998
- SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJORThe Lancet, 1989
- Noncompliance with iron chelation therapy in patients with β thalassaemiaJournal of Psychosomatic Research, 1989